Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers

被引:19
|
作者
Tushar, Tewari [1 ]
Vinod, Thomas [1 ]
Rajan, Sundaram [1 ]
Shashindran, Chanolean [1 ]
Adithan, Chandrasekaran [1 ]
机构
[1] JIPMER, Dept Pharmacol, Pondicherry 605006, India
关键词
D O I
10.1111/j.1742-7843.2006.00039.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Honey is a common food supplement but not many studies have studied honey and drug interaction. This study investigates the influence of 7 days of honey administration on the activity of CYP3A4, CYP2D6 and CYP2CI9 drug-metabolizing enzymes in healthy volunteers by using appropriate biomarker and probe drugs. A within-group pharmacokinetic study was done in 12 healthy volunteers. Urine samples (0-8 hr) were collected after administration of 30 mg of oral dextromethorphan (probe drug for CYP2D6) for analysis of dextromethorphan and dextrorphan. A plasma sample (4 hr) was collected after administration of 200 mg of oral proguanil (probe drug for CYP2C19) for the analysis of proguanil and cycloguanil. Urine samples (0-24 hr) were collected for the analysis of 6 beta-hydroxycortisol (biomarker for CYP3A4). The volunteers were administered honey for 7 days. Subsequently blood and urine samples were collected after drug dosing as before. These samples were analysed for drug and metabolite concentrations in urine and plasma using high performance liquid chromatography method. Seven days of honey administration resulted in statistically significant increase in 24-hr urinary excretion of 6 beta-hydroxyeortisol. However, the metabolic ratios of dextromethorphan and proguanil were not significantly altered after 7 days of honey administration. Honey obtained from Western Ghats of southern India may induce CYP3A4 enzyme activity but not CYP2D6 and CYP2C19 enzyme activities.
引用
收藏
页码:269 / 272
页数:4
相关论文
共 50 条
  • [41] Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6
    Damkier, P
    Brosen, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) : 199 - 209
  • [42] Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes
    Lim, HK
    Duczak, N
    Brougham, L
    Elliot, M
    Patel, K
    Chan, K
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (08) : 1211 - 1219
  • [43] Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population
    Skadric, Ivan
    Stojkovic, Oliver
    INTERNATIONAL JOURNAL OF LEGAL MEDICINE, 2020, 134 (02) : 433 - 439
  • [44] Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population
    Ivan Skadrić
    Oliver Stojković
    International Journal of Legal Medicine, 2020, 134 : 433 - 439
  • [45] Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers
    Donovan, JL
    DeVane, CL
    Chavin, KD
    Taylor, RM
    Markowitz, JS
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) : 519 - 522
  • [46] Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy
    Miguel A. López-García
    Iris A. Feria-Romero
    Héctor Serrano
    Darío Rayo-Mares
    Pietro Fagiolino
    Marta Vázquez
    Consuelo Escamilla-Núñez
    Israel Grijalva
    David Escalante-Santiago
    Sandra Orozco-Suarez
    Pharmacological Reports, 2017, 69 : 504 - 511
  • [47] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Lu, Sijie
    Nand, R. A.
    Yang, J. S.
    Chen, Gang
    Gross, A. S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 285 - 296
  • [48] CYP2D6, CYP2C19, CYP2C9 and CYP3A5 polymorphism in the Spanish population
    Llovo, R.
    Tudoli, I
    Carril, J. C.
    Fernandez-Novoa, L.
    Seoane, S.
    Cacabelos, R.
    NEW TRENDS IN ALZHEIMER AND PARKINSON RELATED DISORDERS: ADPD 2009, 2009, : 53 - 57
  • [49] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Sijie Lu
    R. A. Nand
    J. S. Yang
    Gang Chen
    A. S. Gross
    European Journal of Clinical Pharmacology, 2018, 74 : 285 - 296
  • [50] Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol
    Fang, J
    Baker, GB
    Silverstone, PH
    Coutts, RT
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 1997, 17 (02) : 227 - 233